pressat11 小时
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical ...
The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
ots12 小时
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical ...
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...